TSUMURA & CO.

The Group's principal businesses are centered on pharmaceuticals, with Kampo medicines as the core, and include the cultivation, procurement, manufacture and sale of crude drug ingredients; the manufacture and sale of Kampo extract powders; the manufacture of decoction pieces and contract processing services; the cultivation, procurement, sorting, processing and storage of crude drug ingredients; the sale of pharmaceuticals and food products; and pharmaceutical development through overseas bases, including in the United States. In Japan, the Group focuses on the manufacture and sale of prescription and over-the-counter medicines, developing its pharmaceutical business through 129 formulations, including drug development and Growing formulations, while also selling healthcare products. The Group is promoting the expansion of its traditional Chinese medicine business in China, the development of value-added services for decoction pieces, and the establishment of a traditional Chinese medicine research and development platform. Its long-term management vision is TSUMURA VISION “Cho-WA” 2031. Its sustainability vision is “Bringing the power to live in harmony with nature into the future.” Its materiality policy comprehensively addresses risks and opportunities related to natural capital and climate change. As its basic capital policy, the Group aims to achieve ROE of 10%, an equity ratio of at least 50% and DOE of 5% in fiscal 2031. Under the Second Medium-Term Management Plan (fiscal 2025–fiscal 2027), the Group has identified 5 strategic issues and is promoting stable growth in its Japan business and expansion of its China business.